Estrella completes second dose cohort in STARLIGHT-1 Phase I trial

Estrella Immunopharma (ESLA) reported that it completed the second dose cohort in the Phase I portion of its STARLIGHT-1 Phase I/II clinical trial of EB103.

Accepted by SEC EDGAR 11/06/2025 - 05:17 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Estrella Immunopharma (ESLA) reported that it completed the second dose cohort in the Phase I portion of its STARLIGHT-1 Phase I/II clinical trial of EB103. The company announced the milestone via a press release dated November 3, 2025, which is furnished as Exhibit 99.1 to this report.

Insights

Biotech clinical development analyst

Early clinical milestone disclosed; administrative in nature.

Estrella Immunopharma announced completion of the second dose cohort in the Phase I portion of its STARLIGHT-1 study evaluating EB103. This marks progress within an early-stage safety/tolerability evaluation, which typically precedes dose escalation and broader Phase II testing.

The disclosure is via an 8-K referencing a press release furnished as Exhibit 99.1. The excerpt does not provide efficacy, safety outcomes, or timelines, so the direct impact on near-term valuation is limited based on the provided details.

Subsequent company communications may outline additional cohorts or transitions within STARLIGHT-1. Actual implications depend on future clinical readouts and regulatory interactions as they are disclosed.

8-K Event Classification

2 items: 8.01, 9.01

2 items

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Estrella Immunopharma (ESLA) announce in its 8-K?

The company announced successful completion of the second dose cohort in the Phase I portion of the STARLIGHT-1 Phase I/II trial of EB103.

Which study is involved in Estrella (ESLA)'s update?

The update relates to the STARLIGHT-1 Phase I/II clinical trial evaluating EB103.

When was the Estrella (ESLA) press release issued?

The press release is dated November 3, 2025 and is furnished as Exhibit 99.1.

Where can I find more details from Estrella (ESLA)'s announcement?

Details are in the press release attached as Exhibit 99.1 to the report.

How is the information in Estrella (ESLA)'s 8-K treated?

The information, including Exhibit 99.1, is being furnished and not filed under the Exchange Act.

What stage of development does this represent for EB103?

Completion of the second dose cohort within the Phase I portion of the STARLIGHT-1 trial.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

false 0001844417 0001844417 2025-11-03 2025-11-03 0001844417 ESLA:CommonStockParValue0.0001PerShareMember 2025-11-03 2025-11-03 0001844417 ESLA:WarrantsEachWholeWarrantExercisableForOneShareOfCommonStockAtExercisePriceOf11.50Member 2025-11-03 2025-11-03 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 3, 2025

Estrella Immunopharma, Inc.

(Exact name of registrant as specified in its charter)

Delaware		001-40608		86-1314502
(State or other jurisdiction		(Commission File Number)		(IRS Employer
of incorporation)				Identification Number)

5858 Horton Street, Suite 370 Emeryville, California		94608
(Address of principal executive offices)		(Zip Code)

(510) 318-9098

(Registrant’s telephone number, including area code)

N/A

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act.

Title of each class		Trading Symbol		Name of each exchange  on which registered
Common Stock, par value $0.0001 per share		ESLA		The Nasdaq Stock Market LLC
Warrants, each whole warrant exercisable for one share of Common Stock at an exercise price of $11.50		ESLAW		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933(§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging  growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01 Other Events.

On November 3, 2025, Estrella Immunopharma, Inc. (the “Company”) issued a press release announcing the successful completion of the second dose cohort in the Phase I portion of its STARLIGHT-1 Phase I/II clinical trial of EB103.

A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information in this Item 8.01, including Exhibit 99.1, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 9.01. Financial Statements and Exhibits

(d) Exhibits

Exhibit No.		Description
99.1		Press Release issued by Estrella Immunopharma, Inc., dated November 3, 2025.
104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

1

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	Estrella Immunopharma, Inc.
	By:	/s/ Cheng Liu
	Name:	Cheng Liu
	Title:	Chief Executive Officer
Date: November 6, 2025

2